B+
Bull case
20%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
BTMD
bioteBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Normalized Asteria supply, improved clinic productivity and lower replacement-supplier costs could restore procedure growth and margins. The company expects sequential procedure improvement in the second half, while dietary supplements revenue grew 5.7% in Q2.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-11-04 · AMC.
What can break
Cash declined to $11.2 million at June 30 from $24.1 million at year-end 2025; debt covenants and scheduled repayments warrant monitoring, despite reported June 30 covenant compliance. [#SEC-10Q-2026-08-07]
Momentum
31
Value
71
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.05 · Bull $1.80 · Bear $0.65Analysis 2026-09-25; returns require an exact persisted reference.
Earnings
2026-11-04 · AMC
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-28 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $2.61
Why
Momentum31 · Δ7d -
Value71 · Δ7d -0.3
Sentiment52 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-11-04 · AMC.
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • Cash declined to $11.2 million at June 30 from $24.1 million at year-end 2025; debt covenants and scheduled repayments warrant monitoring, despite reported June 30 covenant compliance. [#SEC-10Q-2026-08-07]
- • Low coverage, unverified analyst revisions and no validated public-company valuation peers limit conviction.
- • The recall has depressed procedure revenue and gross margin, and management no longer expects year-over-year procedure growth in Q3 or Q4.
Catalyst clock
2026-11-04 · AMC
Q2 recall impact and 2026 outlook cut
Lead driver: Value · See fundamentals
Momentum
31
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
71
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.6
Sentiment
52
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 31.4 / Value 70.7 / Sentiment 52.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.05
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-09-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-28
Fundamentals (TTM)
As of 2026-10-28
Market Cap
$41.32M
Beta
1.16
Shares Out
28.68M
P/E (TTM)
2.9
P/S (TTM)
0.58
P/FCF (TTM)
3.28
Rev YoY
-9.5%
EPS YoY
-328.6%
Gross Margin
+66.9%
Op Margin
+12.0%
Net Debt
$104.3M
Current Ratio
1.43
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data